KPTI - Karyopharm/Antengene's selinexor application OK'd in China for endometrial cancer

Antengene announces that China's National Medical Products Administration ((NMPA)) has approved the Investigational New Drug ((IND)) application for a Phase III trial to evaluate the safety and efficacy of selinexor (Xpovio) being co-developed by Karyopharm Therapeutics (KPTI) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). Antengene is currently conducting five late-stage clinical trials of selinexor for the treatment of MM, DLBCL, non-small cell lung cancer, and peripheral T and NK/T-cell lymphoma.Furthermore, Antengene has submitted NDAs for selinexor in multiple Asia Pacific markets and was granted the Priority Review status by China's NMPA and an Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea.Previously (Jan. 4): Karyopharm/Antengene files application for ATG-010 in China for endometrial cancer

For further details see:

Karyopharm/Antengene's selinexor application OK'd in China for endometrial cancer